Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Overcoming the COVID-19 pandemic will require a multi-pronged therapeutic approach that will draw on the expertise of biochemists, virologists, medicinal chemists and synthetic chemists. First-line tactics directly attack the virus itself. This will be done in the form of small-molecule antivirals that inhibit the development of virus particles during infection and replication. Secondary effects of COVID-19 include bacterial infection that sets in when the lungs undergo inflammation and fibrosis, which is a significant contributor to mortality. The team assembled through Carleton (Professor Jeff Manthorpe PI) is well set up through its existing 16-month relationship with Total Synthesis Ltd. (TSL) to work on the necessary synthetic and medicinal chemistry and associated catalyst development to make these challenging drug candidates, which will be screened for antiviral and antibacterial properties in biochemistry labs at McMaster U and uOttawa.
Jeffrey Manthorpe
Sepideh Sharif;Mathieu Morin;Monica Gill;Nalin Chandrasoma;Ryan Sullivan
Total Synthesis Ltd
Chemistry
Manufacturing
Carleton University
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.